An old idea tackling a new problem: Targeted toxins specific for cancer stem cells

Antibodies

Volumn 2, Issue 1, 2013, Pages 82-92

  Waldron, Nate N ^a   Vallera, Daniel A ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cancer stem cells; CD123; CD133; CD44; EpCAM; Immunotoxins; Targeted toxins

Indexed keywords

26292(FV) PE38 KDEL; ANTINEOPLASTIC AGENT; BIVATUZUMAB MERTANSINE; CD123 ANTIGEN; CD133 ANTIGEN; CDTAC149A C178ABC CD133MAB; CELL SURFACE MARKER; CHIHEA125 AMA; CITATUZUMAB BOGATOX; DCD133KDEL; DT388IL3; DTEPCAM23; EC4 ETA; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; OPORTUZUMAB MONATOX; TOXIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BLADDER CARCINOMA; BREAST CANCER; CANCER REGRESSION; CANCER STEM CELL; CAPILLARY LEAK SYNDROME; CELL PROLIFERATION; COLON CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEVER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTRANSAMINASEMIA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TOXIC EPIDERMAL NECROLYSIS;

EID: 84971353298     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib2010082     Document Type: Review

References (47)

1. Kornek, G.; Selzer, E. Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel. Curr. Pharm. Des. 2009, 15, 207-242.
2. Strom, T. B.; Anderson, P. L.; Rubin-Kelley, V. E.; Williams, D. P.; Kiyokawa, T.; Murphy, J. R. Immunotoxins and cytokine toxin fusion proteins. Semin. Immunol. 1990, 2, 467-479.
3. Madhumathi, J.; Verma, R. S. Therapeutic targets and recent advances in protein immunotoxins. Curr. Opin. Microbiol. 2012, 15, 300-309.
4. Choudhary, S.; Mathew, M.; Verma, R. S. Therapeutic potential of anticancer immunotoxins. Drug Discov. Today 2011, 16, 495-503.
5. Eyler, C. E.; Rich, J. N. Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 2008, 26, 2839-2845.
6. Moncharmont, C.; Levy, A.; Gilormini, M.; Bertrand, G.; Chargari, C.; Alphonse, G.; Ardail, D.; Rodriguez-Lafrasse, C.; Magne, N. Targeting a cornerstone of radiation resistance: Cancer stem cell. Cancer Lett. 2012, 322, 139-147.
7. Bonnet, D.; Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730-737.
8. Ten Cate, B.; de Bruyn, M.; Wei, Y.; Bremer, E.; Helfrich, W. Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Curr. Drug Targets 2010, 11, 95-110.
9. Frankel, A.; Liu, J. S.; Rizzieri, D.; Hogge, D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk. Lymphoma 2008, 49, 543-553.
10. Du, X.; Ho, M.; Pastan, I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J. Immunother. 2007, 30, 607-613.
11. Boman, B. M.; Wicha, M. S. Cancer stem cells: A step toward the cure. J. Clin. Oncol. 2008, 26, 2795-2799.
12. Sales, K. M.; Winslet, M. C.; Seifalian, A. M. Stem cells and cancer: An overview. Stem Cell Rev. 2007, 3, 249-255.
13. Zollar, M. CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat. Rev. Cancer 2011, 11, 254-267.
14. Orian-Rousseau, V. CD44, a therapeutic target for metastasising tumours. Eur. J. Cancer 2010, 46, 1271-1277.
15. Börjesson, P. K.; Postema, E. J.; Roos, J. C.; Colnot, D. R.; Marres, H. A.; van Schie, M. H.; Stehle, G.; de Bree, R.; Snow, G. B.; Oyen, W. J.; et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 2003, 9, 3961S-3972S.
16. Sauter, A.; Kloft, C.; Gronau, S.; Bogeschdorfer, F.; Erhardt, T.; Golze, W.; Schroen, C. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int. J. Oncol. 2007, 30, 927-935.
17. Riechelmann, H.; Sauter, A.; Golze, W.; Hanft, G.; Schroen, C.; Hoermann, K.; Erhardt, T.; Gronau, S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 2008, 44, 823-829.
18. Trzpis, M.; McLaughlin, P. M.; de Leij, L. M.; Harmsen, M. C. Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Am. J. Pathol. 2007, 171, 386-395.
19. Imrich, S.; Hachmeister, M.; Gires, O. EpCAM and its potential role in tumor-initiating cells. Cell Adh. Migr. 2012, 6, 30-38.
20. Van der Gun, B. T.; Melchers, L. J.; Ruiters, M. H.; de Leij, L. F.; McLaughlin, P. M.; Rots, M. G. EpCAM in carcinogenesis: The good, the bad or the ugly. Carcinogenesis 2010, 31, 1913-1921.
21. Yamashita, T.; Ji, J.; Budhu, A.; Forgues, M.; Yang, W.; Wang, H. Y.; Jia, H.; Ye, Q.; Qin, L.; Wauthier, E.; et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136, 1012-1024.
22. Takahashi-Yanaga, F.; Kahn, M. Targeting Wnt signaling: Can we safely eradicate cancer stem cells? Clin. Cancer Res. 2010, 16, 3153-3162.
23. Stish, B. J.; Chen, H.; Shu, Y.; Panoskaltsis-Mortari, A.; Vallera, D. A. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin. Cancer Res. 2007, 13, 3058-3067.
24. Moldenhauer, G.; Salnikov, A. V.; Lüttgau, S.; Herr, I.; Anderl, J.; Faulstich, H. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J. Natl. Cancer Inst. 2012, 104, 622-634.
25. Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 2010, 362, 1605-1617.
26. Martin-Killias, P.; Stefan, N.; Rothschild, S.; Plückthun, A.; Zangemeister-Wittke, U. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin. Cancer Res. 2011, 17, 100-110.
27. Kowalski, M.; Entwistle, J.; Cizeau, J.; Niforos, D.; Loewen, S.; Chapman, W.; MacDonald, G. C. A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients. Drug Des. Devel. Ther. 2010, 4, 313-320.
28. Kowalski, M.; Guindon, J.; Brazas, L.; Moore, C.; Entwistle, J.; Cizeau, J.; Jewett, M. A.; MacDonald, G. C. A phase II study of oportuzumab monatox: An immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. J. Urol. 2012, 188, 1712-1718.
29. MacDonald, G. C.; Rasamoelisolo, M.; Entwistle, J.; Cizeau, J.; Bosc, D.; Cuthbert, W.; Kowalski, M.; Spearman, M.; Glover, N. A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des. Devel. Ther. 2009, 2, 105-114.
30. Entwistle, J.; Brown, J. G.; Chooniedass, S.; Cizeau, J.; Macdonald, G. C. Preclinical Evaluation of VB6-845: An Anti-EpCAM Immunotoxin with Reduced Immunogenic Potential. Cancer Biother. Radiopharm. 2012, 27, 582-592.
31. Ferrandina, G.; Petrillo, M.; Bonanno, G.; Scambia, G. Targeting CD133 antigen in cancer. Expert Opin. Ther. Targets 2009, 13, 823-837.
32. Rappa, G.; Fodstad, O.; Lorico, A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008, 26, 3008-3017.
33. Mak, A. B.; Nixon, A. M.; Kittanakom, S.; Stewart, J. M.; Chen, G. I.; Curak, J.; Gingras, A. C.; Mazitschek, R.; Neel, B. G.; Stagljar, I.; et al. Regulation of CD133 by HDAC6 Promotes β-Catenin Signaling to Suppress Cancer Cell Differentiation. Cell Rep. 2012, 2, 951-963.
34. Takenobu, H.; Shimozato, O.; Nakamura, T.; Ochiai, H.; Yamaguchi, Y.; Ohira, M.; Nakagawara, A.; Kamijo, T. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011, 30, 97-105.
35. Damek-Poprawa, M.; Volgina, A.; Korostoff, J.; Sollecito, T. P.; Brose, M. S.; O'Malley, B. W., Jr.; Akintoye, S. O.; DiRienzo. J. M. Targeted inhibition of CD133+ cells in oral cancer cell lines. J. Dent. Res. 2011, 90, 638-645.
36. Waldron, N. N.; Kaufman, D. S.; Oh, S.; Inde, Z.; Hexum, M. K.; Ohlfest, J. R.; Vallera, D. A. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol. Cancer Ther. 2011, 10, 1829-1838.
37. Swaminathan, S. K.; Olin, M. R.; Forster, C. L.; Cruz, K. S.; Panyam, J.; Ohlfest, J. R. Identification of a novel monoclonal antibody recognizing CD133. J. Immunol. Methods 2010, 361, 110-115.
38. Ohlfest, J. R.; Zellmer, D.; Panyam, J.; Swaminathan, S. K.; Oh, S.; Waldron, N. N.; Toma, S.; Vallera, D. A. Immunotoxin targeting CD133+ breast carcinoma cells. Drug Deliv. Transl. Res. 2012, doi 10. 1007/s13346-012-0066-2.
39. Skubitz, A. P. N.; Taras, E. P.; Boylan; K. L. M; Waldron, N. N.; Oh, S.; Panoskaltsis-Mortari, A.; Vallera, D. A. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol. Oncol. 2013, submitted.
40. Rutella, S.; Bonanno, G.; Marone, M.; De Ritis, D.; Mariotti, A.; Voso, M. T.; Scambia, G.; Mancuso, S.; Leone, G.; Pierelli, L. Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45{thorn} lineage-cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15. J. Immunol. 2003, 171, 2977-2988.
41. Suuronen, E. J.; Wong, S.; Kapila, V.; Waghray, G.; Whitman, S. C.; Mesana, T. G.; Ruel, M. Generation of CD133+ cells from CD133-peripheral blood mononuclear cells and their properties. Cardiovasc. Res. 2006, 70, 126-135.
42. Smith, L. M.; Nesterova, A.; Ryan, M. C.; Duniho, S.; Jonas, M.; Anderson, M.; Zabinski, R. F.; Sutherland, M. K.; Gerber, H. P.; Van Orden, K. L.; et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br. J. Cancer 2008, 99, 100-109.
43. Oh, S.; Stish, B. J.; Vickers, S. M.; Buchsbaum, D. J.; Saluja, A. K.; Vallera, D. A. A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. Pancreas 2010, 39, 913-922.
44. Weyergang, A.; Selbo, P. K.; Berstad, M. E.; Bostad, M.; Berg, K. Photochemical internalization of tumor-targeted protein toxins. Lasers Surg. Med. 2011, 43, 721-733.
45. Escoffre, J. M.; Mannaris, C.; Geers, B.; Novell, A.; Lentacker, I.; Averkiou, M.; Bouakaz, A. Doxorubicin liposome-loaded microbubbles for contrast imaging and ultrasound triggered drug delivery. IEEE Trans. Ultrason. Ferroelectr. Freq. Control. 2013, 60, 78-87.
46. Hassan, R.; Broaddus, V. C.; Wilson, S.; Liewehr, D. J.; Zhang, J. Anti-Mesothelin Immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin. Cancer Res. 2007, 13, 7166-7171.
47. Pearson, J. W.; Sivam, G.; Manger, R.; Wiltrout, R. H.; Morgan, A. C., Jr.; Longo, D. L. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice. Cancer Res. 1989, 49, 4990-4995.